One-year Changes in Liver Stiffness Measurement, but not in Alanine Aminotransferase and Controlled Attenuation Parameter, Predict Long-term Liver Outcomes in Patients With Metabolic Dysfunction-associated Steatotic Liver Disease | Synapse
March 3, 2026Open Access
One-year Changes in Liver Stiffness Measurement, but not in Alanine Aminotransferase and Controlled Attenuation Parameter, Predict Long-term Liver Outcomes in Patients With Metabolic Dysfunction-associated Steatotic Liver Disease
Key Points
Lower liver stiffness measurement (LSM) after one year predicts a reduced risk of liver-related events (LRE) in patients with MASLD.
A 1-year reduction in LSM was linked to better long-term liver outcomes, demonstrating its clinical significance.
Metabolic dysfunction-associated steatotic liver disease was the focus of the assessment, highlighting a specific health risk.
Changes in LSM, not alanine aminotransferase or controlled attenuation parameter, were crucial for risk prediction.
Abstract
In patients with MASLD and LSM ≥8 or ≥10 kPa, the % LSM reduction at 1 year was independently associated with lower risk of LRE and LD.